Herta Crauwels, PhD, is an Associate Director in the Clinical Pharmacology Group at Janssen Infectious Diseases, based in Beerse, Belgium. Dr Crauwels was trained as a pharmacist and received her PhD in Pharmaceutical Sciences from the Department of Pharmacology, University of Antwerp, Belgium. She first joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2004, in the Neuroscience Group, working mainly on paliperidone and paliperidone palmitate. In 2007, Dr Crauwels joined Janssen Infectious Diseases (formerly Tibotec) where she was a key contributor on the clinical development program for rilpivirine, leading to regulatory approval for different rilpivirine-containing products. Currently, Dr Crauwels is the clinical pharmacology lead for the different Janssen HIV compounds, rilpivirine, etravirine and darunavir, including the development of new combination products with external partners.